

# Derek Y Chiang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2936832/publications.pdf>

Version: 2024-02-01

53  
papers

17,045  
citations

87888

38  
h-index

175258

52  
g-index

54  
all docs

54  
docs citations

54  
times ranked

27922  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 427-439.	4.1	10
2	ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells. <i>Molecular Cancer Research</i> , 2021, 19, 702-716.	3.4	32
3	A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses. <i>Cancer Medicine</i> , 2020, 9, 225-237.	2.8	11
4	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. <i>Npj Breast Cancer</i> , 2018, 4, 19.	5.2	19
5	Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. <i>Molecular Cancer Research</i> , 2017, 15, 1722-1732.	3.4	119
6	Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?. <i>Journal of Hepatology</i> , 2017, 67, 893-895.	3.7	4
7	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 296-304.	3.7	26
8	PureCN: copy number calling and SNV classification using targeted short read sequencing. <i>Source Code for Biology and Medicine</i> , 2016, 11, 13.	1.7	101
9	Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2015, 5, 61.	5.5	1
10	Co-expression networks identify distinct immune infiltrates in hepatocellular carcinoma. , 2015, 3, .		2
11	Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. <i>Nature Medicine</i> , 2015, 21, 440-448.	30.7	408
12	High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. <i>Nature Medicine</i> , 2015, 21, 1318-1325.	30.7	1,065
13	Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 653-663.	3.3	31
14	Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 295-302.	2.3	42
15	iReckon: Simultaneous isoform discovery and abundance estimation from RNA-seq data. <i>Genome Research</i> , 2013, 23, 519-529.	5.5	123
16	A Robust Method for Transcript Quantification with RNA-Seq Data. <i>Journal of Computational Biology</i> , 2013, 20, 167-187.	1.6	13
17	Identification of driver genes in hepatocellular carcinoma by exome sequencing. <i>Hepatology</i> , 2013, 58, 1693-1702.	7.3	264
18	DiffSplice: the genome-wide detection of differential splicing events with RNA-seq. <i>Nucleic Acids Research</i> , 2013, 41, e39-e39.	14.5	138

#	ARTICLE	IF	CITATIONS
19	Integrating Prior Knowledge in Multiple Testing under Dependence with Applications to Detecting Differential DNA Methylation. <i>Biometrics</i> , 2012, 68, 774-783.	1.4	35
20	A Robust Method for Transcript Quantification with RNA-seq Data. <i>Lecture Notes in Computer Science</i> , 2012, , 127-147.	1.3	1
21	Nuclear factor I/B is an oncogene in small cell lung cancer. <i>Genes and Development</i> , 2011, 25, 1470-1475.	5.9	142
22	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	1.3	205
23	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011, 43, 964-968.	21.4	270
24	Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies. <i>Cancer Research</i> , 2011, 71, 7587-7596.	0.9	70
25	Suppression of lung adenocarcinoma progression by Nkx2-1. <i>Nature</i> , 2011, 473, 101-104.	27.8	383
26	FDM: a graph-based statistical method to detect differential transcription using RNA-seq data. <i>Bioinformatics</i> , 2011, 27, 2633-2640.	4.1	50
27	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010, 463, 899-905.	27.8	3,331
28	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. <i>Nature Genetics</i> , 2010, 42, 715-721.	21.4	642
29	A probabilistic framework for aligning paired-end RNA-seq data. <i>Bioinformatics</i> , 2010, 26, 1950-1957.	4.1	23
30	MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery. <i>Nucleic Acids Research</i> , 2010, 38, e178-e178.	14.5	946
31	Cancer gene discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 52, 921-929.	3.7	173
32	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	3.7	211
33	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2009, 69, 7385-7392.	0.9	978
34	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. <i>Nature Biotechnology</i> , 2009, 27, 264-274.	17.5	194
35	Mapping duplicated sequences. <i>Nature Biotechnology</i> , 2009, 27, 1001-1002.	17.5	5
36	High-resolution mapping of copy-number alterations with massively parallel sequencing. <i>Nature Methods</i> , 2009, 6, 99-103.	19.0	462

#	ARTICLE	IF	CITATIONS
37	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	3.7	206
38	Pathogenesis of hepatocellular carcinoma and molecular therapies. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 186-194.	2.3	118
39	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. <i>Journal of Clinical Investigation</i> , 2009, 119, 465-477.	8.2	298
40	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. <i>Journal of Clinical Investigation</i> , 2009, 119, 1727-1740.	8.2	230
41	High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 591-603.	2.8	101
42	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	1.3	644
43	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.9	589
44	<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4275-4283.	7.0	916
45	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	27.0	1,148
46	Genomics and Signaling Pathways in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2007, 27, 055-076.	3.6	491
47	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007, 450, 893-898.	27.8	1,020
48	Determining Physical Constraints in Transcriptional Initiation Complexes Using DNA Sequence Analysis. <i>PLoS ONE</i> , 2007, 2, e1199.	2.5	8
49	Conservation and Evolution of Cis-Regulatory Systems in Ascomycete Fungi. <i>PLoS Biology</i> , 2004, 2, e398.	5.6	207
50	MONKEY: identifying conserved transcription-factor binding sites in multiple alignments using a binding site-specific evolutionary model. <i>Genome Biology</i> , 2004, 5, R98.	9.6	134
51	Position specific variation in the rate of evolution in transcription factor binding sites. <i>BMC Evolutionary Biology</i> , 2003, 3, 19.	3.2	130
52	Phylogenetically and spatially conserved word pairs associated with gene-expression changes in yeasts. <i>Genome Biology</i> , 2003, 4, R43.	9.6	44
53	Vav2 Is an Activator of Cdc42, Rac1, and RhoA. <i>Journal of Biological Chemistry</i> , 2000, 275, 10141-10149.	3.4	226